INVESTIGADORES
RUIZ Maria Laura
artículos
Título:
Induction of P-glycoprotein expression and activity by prolactin in female rat liver
Autor/es:
CERÉ, LUCILA I.; SEDLMEIER, MARÍA G.; SEMENIUK, MARIANA; LUQUITA, MARCELO G.; FRANCÉS, DANIEL; RONCO, MARÍA T.; RIGALLI, JUAN PABLO; RUIZ, MARÍA L.; CATANIA, VIVIANA A.
Revista:
LIFE SCIENCES
Editorial:
PERGAMON-ELSEVIER SCIENCE LTD
Referencias:
Año: 2021 vol. 287
ISSN:
0024-3205
Resumen:
Aim: P-glycoprotein (P-gp) plays a critical role in the excretion of xenobiotics into bile. Previous studies have demonstrated that prolactin (PRL) regulates biotransformation and bile salt transport. Here we investigate whether the capability of the liver to transport xenobiotics into bile is altered in hyperprolactinemic states studying the modulation of hepatic P-gp by PRL. Methods: We used lactating post-partum rats (PP), as a model of physiological hyperprolactinemia (15 and 21 days after delivery: PP15 and PP21, respectively), and ovariectomized rats treated with PRL (300 μg/day, 7 days, via osmotic minipumps, OVX + PRL). Hepatic P-gp expression and activity were evaluated by western blotting and using rhodamine 123 as substrate in vivo, respectively. Since P-gp is encoded by Mdr1a and Mdr1b in rodents, we quantified their expression by qPCR in primary hepatocyte cultures exposed to 0.1 μg/ml of PRL after 12 h. To further study the mechanism of hepatic P-gp modulation by PRL, hepatocytes were pretreated with actinomycin D and then exposed to PRL (0.1 μg/ml) for 12 h. Key findings: We found increased hepatic P-gp protein expression and activity in PP15 and OVX + PRL. Also, a significant increase in Mdr1a and Mdr1b mRNA levels was observed in primary hepatocyte cultures exposed to PRL, pointing out the hormone direct action. Actinomycin D prevented these increases, confirming a transcriptional up-regulation of P-gp by PRL. Significance: These findings suggest the possibility of an increased biliary excretion of xenobiotics substrates of Pgp, including therapeutic agents, affecting their pharmaco/toxicokinetics in hyperprolactinemic situations.